Telotristat Etiprate - Expanded Treatment for Patients With Carcinoid Syndrome Symptoms

Official Title

A Multicentre, Long-term Extension Study to Further Evaluate the Safety and Tolerability of Telotristat Etiprate (LX1606)


The primary objective of this study is to evaluate the long-term safety and tolerability of orally administered telotristat etiprate.

Trial Description

Primary Outcome:

  • Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
Secondary Outcome:
  • Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ-C30) Score at Each Visit
  • Change From Baseline in Gastrointestinal Symptoms of Carcinoid Neuroendocrine Tumours (GI.NET21) Score at Each Visit
  • Percentage of Participants With Adequate Relief as Per Subjective Global Assessment Question
  • Change From Baseline in Subjective Global Assessment of Carcinoid Syndrome Symptoms on 11-Point Numeric Scale at Each Visit

View this trial on

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.


Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society